Tag Archives: FFPE

Formalin-fixed paraffin-embedded (FFPE) tissues are the most abundant archivable specimens in clinical tissue banks, but unfortunately incompatible with single-cell level transcriptome sequencing due to RNA...

Researchers at the University of Freiburg aimed to compare the potential of standard RNA-sequencing (RNA-Seq) and 3′ massive analysis of c-DNA ends (MACE) RNA-sequencing for the analysis of fresh...

Initiatives such as The Cancer Genome Atlas (TCGA) and International Cancer Genome Consortium (ICGC) have generated high-quality, multi-platform molecular data from thousands of frozen tumor...

This is the first companion diagnostic to detect gene fusions across all solid tumors; Caris expects to submit for Pre-Market Approval later this year Caris Life Sciences, a leading innovator in molecular...

Cofactor Genomics, a clinical RNA sequencing and translational assay developer, announced today the commercial launch of Paragon, a solid tumor immune-profiling assay requiring only two FFPE...

December 18, 2017, 11AM EST, 4PM GMT, 5PM CET, 8AM PST RNA derived from formalin fixed, paraffin embedded (FFPE) tissues are invaluable for gene expression analysis of a myriad of disease states. However, the process of fixing the tissue and embedding ...

OmniSeq Inc scientists have developed a next-generation sequencing assay to quantify biomarkers of the host immune response in formalin-fixed, paraffin-embedded (FFPE) tumor specimens. This assay aims to provide clinicians with a comprehensive characterization of the immunological tumor microenvironment as a ...

Cofactor Genomics, developer of a leading platform for RNA sequencing and expression analysis, today announced $18M in financing led by Menlo Ventures with major participation from existing investor Data Collective (DCVC) and new investor Ascension Ventures, and participation from existing ...

RNA-sequencing (RNA-seq) has emerged as one of the most sensitive tool for gene expression analysis. Among the library preparation methods available, the standard poly(A) + enrichment provides a comprehensive, detailed, and accurate view of polyadenylated RNAs. However, on samples of ...

Agilent Technologies Inc. (NYSE: A) and Agendia, Inc. today jointly announced an agreement to expand their relationship to include the development of an RNA-Seq kit version of Agendia’s currently marketed MammaPrint and BluePrint tests. Agendia’s MammaPrint test provides High-Risk or ...